- /
- Supported exchanges
- / US
- / AGIO.NASDAQ
Agios Pharm (AGIO NASDAQ) stock market data APIs
Agios Pharm Financial Data Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Agios Pharm (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Agios Pharm data using free add-ons & libraries
Get Agios Pharm Fundamental Data
Agios Pharm Fundamental data includes:
- Net Revenue: 141 M
- EBITDA: -413 884 000
- Earnings Per Share: -6
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -1.32
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Agios Pharm News
New
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
Agios Pharmaceuticals has seen its share price bounce around in recent years, while expectations around its rare disease franchise keep shifting with new data and regulatory updates. With the stock la...
Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...
This article first appeared on GuruFocus. Total Net Revenue: $55.4 million in Q3 2026, more than 4x the $12.9 million in Q3 2025. US Net Revenue: $48.7 million, driven by the AQVESME thalassemia laun...
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago. These figu...
Agios Pharmaceuticals: Q3 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $65 million in its third quarter. The Cambridge, Massachusetts-based company said ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.